

## APC/Cyanine7 anti-mouse I-A/I-E Antibody

<b>Catalog# / Size</b>	107627 / 25 µg 107628 / 100 µg
<b>Clone</b>	M5/114.15.2
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	MHC class II
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2 <sup>b,d,q,r</sup> bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Activated C57BL/6 mouse spleen cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-A <sup>b</sup> , I-A <sup>d</sup> , I-A <sup>q</sup> , I-E <sup>d</sup> , and I-E <sup>k</sup> MHC class II alloantigens from mice carrying H-2 <sup>P,r,q,b,d,u</sup> haplotypes. Clone M5/114.15.2 however does not react with I-A <sup>f</sup> , I-A <sup>k</sup> , or I-A <sup>s</sup> MHC class II alloantigens. <sup>1</sup>  Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1</sup> , immunohistochemistry of frozen sections <sup>2,3,6</sup> , <i>in vitro</i> and <i>in vivo</i> blocking of antigen presentation or ligand binding <sup>4-7</sup> , and spatial biology (IBEX) <sup>17,18</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Bhattacharya A, <i>et al.</i> 1981. <i>J. Immunol.</i> 127:2488. (IP)</li> <li>2. Viville S, <i>et al.</i> 1993. <i>Cell</i> 72:635. (IHC)</li> <li>3. Nelson AJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2453. (IHC)</li> <li>4. Shi Y, <i>et al.</i> 1998. <i>J. Exp. Med.</i> 187:367. (Block)</li> <li>5. Yamashita I, <i>et al.</i> 1993. <i>Int. Immunol.</i> 5:1139.</li> <li>6. Guo M, <i>et al.</i> 1995. <i>Zygote</i> 3:65. (IHC)</li> <li>7. Kim A, <i>et al.</i> 2004. <i>Exp. Mol. Med.</i> 36:428. (Block)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

8. Luckashenak NA, *et al.* 2006. *J. Immunol.* 177:5177.
9. Venanzi ES, *et al.* 2007. *J. Immunol.* 179:5693.
10. Christensen SR, *et al.* 2006. *Immunity* 25:417. [PubMed](#)
11. Matte-Martone C, *et al.* 2008. *Blood* 111:3884. [PubMed](#)
12. De Pascalis R, *et al.* 2008. *Infect. Immun.* 76:4311. [PubMed](#)
13. Kuns RD, *et al.* 2009. *Blood* 113:5999. [PubMed](#)
14. Sabatino JJ, *et al.* 2011. *J. Exp. Med.* 208:81. [PubMed](#)
15. Draber P, *et al.* 2011. *Mol Cell Biol.* 22:4550. [PubMed](#)
16. Fu H, *et al.* 2014. *Nat Commun.* 5:3436. [PubMed](#)
17. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
18. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Garber C, *et al.* 2019. *Nat Neurosci.* 1.802777778. [PubMed](#)
2. Wong Fok Lung T, *et al.* 2020. *Nat Microbiol.* 141:5. [PubMed](#)
3. Engel O, *et al.* 2015. *Stroke.* 46: 3232 - 3240. [PubMed](#)
4. Lauterbach MA, *et al.* 2020. *Immunity.* 51(6):997-1011.e7.. [PubMed](#)
5. Rødahl I, *et al.* 2021. *STAR Protoc.* 2:100842. [PubMed](#)
6. Shmuel-Galia L, *et al.* 2021. *Immunity.* 54(6):1137-1153.e8. [PubMed](#)
7. Lancaster JN, *et al.* 2019. *Nat Commun.* 10:2220. [PubMed](#)
8. Li Y, *et al.* 2021. *Basic Res Cardiol.* 116:30. [PubMed](#)
9. Chen WS, *et al.* 2021. *Cell Rep.* 37:109974. [PubMed](#)
10. Jtte BB, *et al.* 2021. *iScience.* 24(8):102833. [PubMed](#)
11. Molina-Sanchez P, *et al.* 2020. *Gastroenterology.* 2203:159. [PubMed](#)
12. Go DM, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:715. [PubMed](#)
13. Li K, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
14. Super M, *et al.* 2021. *Nat Biomed Eng.* Online ahead of print. [PubMed](#)
15. Zhao Y, *et al.* 2021. *Int Immunopharmacol.* 93:107406. [PubMed](#)
16. Hilpert C, *et al.* 2016. *J Immunol.* 197: 2780 - 2786. [PubMed](#)
17. An J, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-13629-0. [PubMed](#)
18. Liang Z, *et al.* 2020. *Pain.* 161:2089. [PubMed](#)
19. Hore ZL, *et al.* 2021. *Wellcome Open Res.* 6:68. [PubMed](#)
20. Peres-Emidio EC, *et al.* 2022. *Front Cell Infect Microbiol.* 12:811474. [PubMed](#)
21. Salei N, *et al.* 2020. *J Am Soc Nephrol.* 31:257. [PubMed](#)
22. Chun E, *et al.* 2020. *Immunity.* 51(5):871-884.e6.. [PubMed](#)
23. Bellelli R *et al.* 2018. *Molecular cell.* 70(4):707-721 . [PubMed](#)
24. Riquelme SA, *et al.* 2020. *Cell Metabolism.* 31(6):1091-1106.e6. [PubMed](#)
25. Neupane AS, *et al.* 2020. *Cell.* 183(1):110-125.e11. [PubMed](#)
26. DeVito NC, *et al.* 2021. *Cell Reports.* 35(5):109071. [PubMed](#)
27. Jia Q, *et al.* 2021. *Theranostics.* 4699:11. [PubMed](#)
28. Xu Z, *et al.* 2020. *Cancer Immunol Res.* 1354:8. [PubMed](#)
29. Céspedes P, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:3214. [PubMed](#)
30. Acker KP, *et al.* 2019. *iScience.* 19:281. [PubMed](#)
31. Yong L, *et al.* 2022. *Nat Commun.* 13:4255. [PubMed](#)
32. Bauer T, *et al.* 2021. *Life (Basel).* 11:. [PubMed](#)
33. Garland KM, *et al.* 2021. *Front Immunol.* 12:753472. [PubMed](#)
34. Guldner IH, *et al.* 2020. *Cell.* 183(5):1234-1248.e25. [PubMed](#)
35. Liang J, *et al.* 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
36. França TT, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
37. Covarrubias AJ, *et al.* 2020. *Nat Metab.* 1265:2. [PubMed](#)
38. Ni J, *et al.* 2020. *Immunity.* 52(6):1075-1087.e8. [PubMed](#)
39. Lim S, *et al.* 2016. *PLoS One.* 11: 0155689. [PubMed](#)
40. Choi EW, *et al.* 2020. *Sci Rep.* 10:12001. [PubMed](#)
41. Liu C *et al.* 2019. *Immunity.* 51(2):381-397 . [PubMed](#)
42. Terrazas M 2014. *Int J Parasit.* 44 613 . [PubMed](#)
43. Chandra J, *et al.* 2016. *Immunol Cell Biol.* 10.1038/icb.2016.83. [PubMed](#)
44. Ahn D, *et al.* 2021. *Cell Reports.* 35(9):109196. [PubMed](#)
45. Bhattacharya A, *et al.* 2018. *Neuropsychopharmacology.* 43:2586. [PubMed](#)
46. Yang B, *et al.* 2021. *Cell Biosci.* 11:28. [PubMed](#)
47. Han Y, *et al.* 2022. *Int J Biol Sci.* 18:5653. [PubMed](#)
48. Lowe PP, *et al.* 2020. *J Neuroinflammation.* 0.913888889. [PubMed](#)
49. Bent EH, *et al.* 2021. *Nat Commun.* 12:6218. [PubMed](#)
50. Pizzurro GA, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
51. Hofmann J, *et al.* 2021. *Front Immunol.* 11:599495. [PubMed](#)
52. Mohammadi MR, *et al.* 2021. *Commun Biol.* 4:685. [PubMed](#)
53. Bellomo A, *et al.* 2020. *Immunity.* 53(1):127-142.e7. [PubMed](#)
54. Maniati E, *et al.* 2020. *Cell Rep.* 30:525. [PubMed](#)
55. Sung PS, *et al.* 2022. *JCI Insight.* . [PubMed](#)
56. Wong NR, *et al.* 2021. *Immunity.* 54:2072. [PubMed](#)
57. Ghazal R, *et al.* 2016. *Neoplasia.* 18: 294-306. [PubMed](#)
58. Baumann D, *et al.* 2020. *Nat Commun.* 1.969444444. [PubMed](#)
59. Li J, *et al.* 2019. *iScience.* 16:468. [PubMed](#)
60. Mello AM, *et al.* 2022. *Oncogenesis.* 11:56. [PubMed](#)
61. Willemssen J, *et al.* 2021. *Cell Rep.* 37:109977. [PubMed](#)
62. Ding L *et al.* 2018. *Cell reports.* 25(11):2972-2980 . [PubMed](#)
63. Kitaura F, *et al.* 2019. *PLoS One.* 14:e0220199. [PubMed](#)
64. Hayashida E, *et al.* 2019. *J Neuroinflammation.* 0.789583333. [PubMed](#)
65. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
66. Schnoegl D, *et al.* 2022. *Front Immunol.* 13:909270. [PubMed](#)

67. Siolas D, *et al.* 2021. Cell Reports. 36(8):109578. [PubMed](#)
68. Xu C, *et al.* 2021. Cell Reports. 35(11):109235. [PubMed](#)
69. Moreno M *et al.* 2014. The Journal of Neuroscience. 34(24):8175-85. [PubMed](#)
70. Jin J, *et al.* 2020. Cell Reports. 30(12):4124-4136. [PubMed](#)
71. Lavoie S, *et al.* 2020. Gastroenterology. 158:1359. [PubMed](#)
72. Gundra UM, *et al.* 2017. Nat Immunol. 1.195833333. [PubMed](#)
73. Seenappa LM, *et al.* 2022. NPJ Vaccines. 7:128. [PubMed](#)
74. Rosen SF, *et al.* 2022. Genome Med. 14:108. [PubMed](#)
75. Sheng D, *et al.* 2022. J Immunother Cancer. 10:1. [PubMed](#)
76. Schwartz C, *et al.* 2014. Proc Natl Acad Sci U S A. 111:5169. [PubMed](#)
77. Jaeger N, *et al.* 2020. Cell Rep. 33:108331. [PubMed](#)
78. Smith HJ, *et al.* 2018. Cancer. 124:4657. [PubMed](#)
79. Boguslawski KM, *et al.* 2020. Sci Adv. 6:eaax7515. [PubMed](#)
80. Wang L, *et al.* 2020. J Nanobiotechnology. 18:38. [PubMed](#)
81. Hsu HP, *et al.* 2021. J Biol Chem. 296:100419. [PubMed](#)
82. Kerdidani D, *et al.* 2022. J Exp Med. 219:1. [PubMed](#)
83. Dai B, *et al.* 2021. Cell Reports Medicine. 2(8):100381. [PubMed](#)
84. Zysset D, *et al.* 2016. Nat Commun. 7:13151. [PubMed](#)
85. Castillo V, *et al.* 2015. PLoS One. 10: 0136620. [PubMed](#)
86. Henningson L, *et al.* 2010. Infect Immun. 78:3785. [PubMed](#)
87. Deniset JF *et al.* 2019. Immunity. 51(1):131-140. [PubMed](#)
88. Sethuraman SN, *et al.* 2020. Theranostics. 10:3397. [PubMed](#)
89. Deets KA, *et al.* 2021. Elife. 10:1. [PubMed](#)
90. Matei DE, *et al.* 2021. Med (N Y). 2:864. [PubMed](#)

**RRID** AB\_1659252 (BioLegend Cat. No. 107627)  
 AB\_2069377 (BioLegend Cat. No. 107628)

## Antigen Details

<b>Structure</b>	MHC class II
<b>Distribution</b>	B cell and activated T cells, APCs of the H-2 <sup>b,d,q,r</sup> bearing mice
<b>Function</b>	Antigen presentation
<b>Ligand/Receptor</b>	CD3/TCR, CD4
<b>Cell Type</b>	Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Molecular Family</b>	MHC Antigens
<b>Antigen References</b>	1. Watts C. 1997. <i>Ann. Rev. Immunol.</i> 15:821. 2. Pamer E, <i>et al.</i> 1998. <i>Ann. Rev. Immunol.</i> 16:323.
<b>Gene ID</b>	<a href="#">14961</a> <a href="#">14969</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Biotin anti-mouse I-A/I-E, FITC anti-mouse I-A/I-E, PE anti-mouse I-A/I-E, Purified anti-mouse I-A/I-E, PE/Cyanine5 anti-mouse I-A/I-E, APC anti-mouse I-A/I-E, Alexa Fluor® 488 anti-mouse I-A/I-E, Alexa Fluor® 647 anti-mouse I-A/I-E, Pacific Blue™ anti-mouse I-A/I-E, Alexa Fluor® 700 anti-mouse I-A/I-E, PerCP/Cyanine5.5 anti-mouse I-A/I-E, PerCP anti-mouse I-A/I-E, APC/Cyanine7 anti-mouse I-A/I-E, PE/Cyanine7 anti-mouse I-A/I-E, Brilliant Violet 421™ anti-mouse I-A/I-E, Brilliant Violet 510™ anti-mouse I-A/I-E, Purified anti-mouse I-A/I-E (Maxpar® Ready), Brilliant Violet 605™ anti-mouse I-A/I-E, Brilliant Violet 650™ anti-mouse I-A/I-E, Brilliant Violet 711™ anti-mouse I-A/I-E, Brilliant Violet 785™ anti-mouse I-A/I-E, PE/Dazzle™ 594 anti-mouse I-A/I-E, Alexa Fluor® 594 anti-mouse I-A/I-E, APC/Fire™ 750 anti-mouse I-A/I-E, TotalSeq™-A0117 anti-mouse I-A/I-E, Ultra-LEAF™ Purified anti-mouse I-A/I-E, TotalSeq™-B0117 anti-mouse I-A/I-E, TotalSeq™-C0117 anti-mouse I-A/I-E, Spark Blue™ 550 anti-mouse I-A/I-E, PE/Fire™ 640 anti-mouse I-A/I-E, Spark YG™ 581 anti-mouse I-A/I-E, PE/Fire™ 810 anti-mouse I-A/I-E, Spark UV™ 387 anti-mouse I-A/I-E

## Product Data



C57BL/6 mouse splenocytes were stained with anti-mouse CD11b FITC and I-A/I-E (clone M5/114.15.2) APC/Cyanine7 (left) or Rat IgG2b, κ isotype control (right).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587